Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Sharanjot Saini, Rajvir Dahiya, Yuichiro Tanaka, Mohd Saif Zaman, Guoren Deng, Varahram Shahryari, Shahana Majid, Soichiro Yamamura, Sumit Arora, Inik Chang
Publikováno v:
Cancer Research. 72:3618-3630
Tumor recurrence in prostate cancer has been attributed to the presence of CD44-expressing tumor-initiating cells. In this study, we report that miR-708 is a key negative regulator of this CD44+ subpopulation of prostate cancer cells, with important
Autor:
Bethany A. Kerr, Koran S. Harris, Aleksander Skardal, Taylor C. Peak, Stephanie Sanders, Lihong Shi
Publikováno v:
Cancer Research. 77:1983-1983
Tyrosine kinase receptors have been shown to drive prostate cancer progression and metastasis. In particular CD117/c-kit expression is upregulated during tumor progression with the highest levels being expressed in bone metastases. In addition, the n
Publikováno v:
Cancer Research. 76:C18-C18
Introduction: Bone metastatic prostate cancer is common, incurable and, hallmarked by extensive osteoblast driven bone formation that greatly impacts the patient's quality of life. To generate new cures a better understanding of the cellular and mole
Publikováno v:
Cancer Research. 75:429-429
Obesity has been shown to increase prostate cancer (PCa) progression and disease severity in men. In previous studies, we showed that diet-induced obesity (DIO, 60 kcal% fat) increased the incidence and severity of invasive adenocarcinomas in HiMyc t
Autor:
Rajvir Dahiya, Yuichiro Tanaka, Shinichiro Fukuhara, Shahana Majid, Soichiro Yamamura, Sumit Arora, Inik Chang, Guoren Deng, Varahram Shahryari, Takeshi Chiyomaru, Sharanjot Saini
Publikováno v:
Cancer Research. 73:5322-5322
A challenging aspect of prostate cancer (PCa) is the high rates of recurrence associated with the disease. About 40% of men with localized prostate cancer suffer from relapse after initial therapy. In these cases, androgen ablation therapy is used to